Drug Profile
SAR 421869
Alternative Names: MY07A gene therapy - Oxford Biomedica; Myosin VIIA gene therapy; SAR-421869; Usher syndrome gene therapy - Oxford BioMedica/Sanofi; UshStatLatest Information Update: 06 Oct 2021
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Developer Sanofi
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Usher syndromes